Faruqi & Faruqi, LLP is Investigating Intersect ENT, Inc. (XENT) on Behalf of its Shareholders
NEW YORK, June 18, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential breaches of fiduciary duty by the board of directors at Intersect ENT, Inc. ("Intersect" or the "Company") (NASDAQ: XENT).
Request more information now by clicking here: www.faruqilaw.com/XENT. There is no cost or obligation to you.
Take Action
If you currently own Intersect stock and would like to discuss your legal rights, please visit www.faruqilaw.com/XENT. You can also contact us by calling Nina Varindani at (212) 983-9330 or by sending an e-mail to [email protected]. Faruqi & Faruqi, LLP also encourages anyone with information regarding Intersect's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
CONTACT: Nina M. Varindani FARUQI & FARUQI, LLP 685 Third Avenue, 26th Floor New York, NY 10017 [email protected] Telephone: (212) 983-9330
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lincoln National Corporation ("Lincoln National" or "the Company") and certain of its...
TSX VENTURE COMPANIES
BULLETIN V2024-1211
ALPHAMIN RESOURCES CORP. ("AFM")BULLETIN TYPE: Declaration of DividendBULLETIN DATE: April 26, 2024TSX Venture Tier 2 Company
The Issuer has declared the following dividend:
Dividend Amount per Common...
Wall Financial Corporation (the "Company") released its operating results and financial statements for the three months and year ended January 31, 2024. The Company recorded net earnings and comprehensive income attributable to shareholders of the...
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...
Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New...